• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
2
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.哒嗪类化合物作为用于治疗帕金森病或额颞叶痴呆的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
3
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
4
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.新型化合物作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Apr 26;16(5):760-761. doi: 10.1021/acsmedchemlett.5c00218. eCollection 2025 May 8.
5
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2025 Apr 1;16(4):538-539. doi: 10.1021/acsmedchemlett.5c00143. eCollection 2025 Apr 10.
6
Exploring the therapeutic potential of NLRP3 inhibitors in Parkinson's Disease: a systematic review of in-vivo studies.探索NLRP3抑制剂在帕金森病中的治疗潜力：一项体内研究的系统综述
Inflammopharmacology. 2025 Apr 21. doi: 10.1007/s10787-025-01733-x.
7
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
8
Novel Pyrido[3,4-]pyrimidin-4-one and Pyrimido[5,4-]pyrimidin-4-one Derivatives as TREM2 Agonists for Treating Parkinson's Disease.新型吡啶并[3,4-]嘧啶-4-酮和嘧啶并[5,4-]嘧啶-4-酮衍生物作为治疗帕金森病的TREM2激动剂
ACS Med Chem Lett. 2025 Apr 2;16(5):715-716. doi: 10.1021/acsmedchemlett.5c00145. eCollection 2025 May 8.
9
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.新型三嗪衍生物作为治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
10
Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.哒嗪衍生物作为用于治疗哮喘、慢性阻塞性肺疾病、帕金森病和阿尔茨海默病的NLRP3抑制剂
ACS Med Chem Lett. 2023 Aug 1;14(8):1047-1048. doi: 10.1021/acsmedchemlett.3c00311. eCollection 2023 Aug 10.

引用本文的文献

1
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.

本文引用的文献

1
Role of NLRP3 inflammasome in central nervous system diseases.NLRP3炎性小体在中枢神经系统疾病中的作用。
Cell Biosci. 2024 Jun 7;14(1):75. doi: 10.1186/s13578-024-01256-y.
2
Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons.NLRP3在帕金森病中的作用：特异性激活，尤其是在多巴胺能神经元中。
Heliyon. 2024 Mar 28;10(7):e28838. doi: 10.1016/j.heliyon.2024.e28838. eCollection 2024 Apr 15.
3
NLRP3 inflammasome signalling in Alzheimer's disease.NLRP3 炎性小体在阿尔茨海默病中的作用机制。
Neuropharmacology. 2024 Jul 1;252:109941. doi: 10.1016/j.neuropharm.2024.109941. Epub 2024 Mar 31.
4
Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action.通过 AMP 激活的蛋白激酶通路靶向阿尔茨海默病的植物化学物质、作用及作用机制。
Biomed Pharmacother. 2024 Apr;173:116373. doi: 10.1016/j.biopha.2024.116373. Epub 2024 Mar 4.
5
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.糖原合酶激酶 3β（GSK-3β）抑制剂在帕金森病中的治疗潜力：探索被忽视的途径。
Mol Neurobiol. 2024 Sep;61(9):7092-7108. doi: 10.1007/s12035-024-04003-z. Epub 2024 Feb 17.
6
Molecular crosstalk between circadian clock and NLRP3 inflammasome signaling in Parkinson's disease.帕金森病中昼夜节律与NLRP3炎性小体信号通路之间的分子串扰
Heliyon. 2024 Jan 14;10(2):e24752. doi: 10.1016/j.heliyon.2024.e24752. eCollection 2024 Jan 30.

作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。

Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.

作者信息

Sabnis Ram W

机构信息

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

出版信息

ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.

DOI:10.1021/acsmedchemlett.4c00343
PMID:39140054
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318011/
Abstract

Provided herein are novel compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating Alzheimer's disease and Parkinson's disease, and processes for preparing such compounds.

摘要

本文提供了作为NLRP3抑制剂的新型化合物、药物组合物、此类化合物在治疗阿尔茨海默病和帕金森病中的用途以及制备此类化合物的方法。